Pressmeddelande

BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I

Cision Publicerad: 14 Jun 08:45

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK 60 million rights issue of units will fund a phase I study with the breast cancer vaccine candidate ES2B-C001, building on promising preclinical results. The capital raise will also support the cytomegalovirus vaccine discovery project in the Evaxion collaboration, and other working capital including in the grant sponsored research and development.

Read the full article at biostock.se:

https://www.biostock.se/2024/06/rights-issue-takes-expres2ion-breast-cancer-vaccine-to-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om ExpreS2ion Biotech

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!